Search
Vaccines Treatment Options
A collection of 948 research studies where Vaccines is the interventional treatment. These studies are located in the United States. Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
265 - 276 of 948
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults
Completed
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of polyvalent env (A,B,C,A/E)/gag (C) DNA and gp120 (A,B,C,A/E) protein vaccines (PDPHV201401) co-administered together with or without adjuvant in repeated doses in healthy, HIV-uninfected adults
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/07/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: HIV Infections
Flublok or Fluzone With Advax-CpG55.2 or AF03
Completed
This is a Phase I, randomized, double blinded, clinical trial in up to 240 males and non-pregnant females, 18-45 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of either the 2018/2019 seasonal Fluzone or Flublok Quadrivalent Influenza Vaccine (QIV) manufactured by Sanofi Pasteur (SP) given without adjuvant or with one of two adjuvant formulations, AF03 or Advax-CpG55.2. Eig... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
03/28/2024
Locations: Emory University School of Medicine, Atlanta, Georgia +7 locations
Conditions: Influenza, Influenza Immunisation
Vaccination for Recovered Inpatients With COVID-19 (VATICO)
Completed
In this Phase 4, open-label trial, participants of the ACTIV-3/TICO clinical trial at selected sites who received certain pre-specified blinded investigational agents or placebo as part of that trial, and who have since achieved sustained recovery, and who are still \[TICO assignment\] blinded and who are still within 28 to 90 days after initial TICO randomization, will be randomized in this 2x2 factorial design to one of four groups: (i) immediate versus 12 week deferral of first dose administr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Blvd, Los Angeles, California +29 locations
Conditions: Covid19
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults
Completed
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-24 at 3 dose levels compared to PCV20 in adults aged 50 to 64 years of age in Phase 2.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/25/2024
Locations: CenExel RCA, Hollywood, Florida +12 locations
Conditions: Pneumococcal Vaccines
Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer
Terminated
The investigator is developing an immune therapy against pancreatic cancer. Immune cells, known as "T cells with tumor killing capacity", are involved in this immune therapy. In mice with pancreatic cance there is evidence that one tetanus toxoid (TT) vaccination (that patients receive from childhood) combined with Gemcitabine activates these killer T cells. (Gemcitabine improves T cell responses) These killer T cells are able to destroy tumor cells uploaded with TT protein (such studies are pla... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/25/2024
Locations: Albert Einstein College of Medicine, Bronx, New York
Conditions: Pancreatic Cancer
Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1
Completed
The purpose of this study is to compare the safety and immunogenicity over a 9-month period of five different dosages of Ad4-H5-Vtn in volunteers (Vaccinees) who receive three doses of the study vaccine or placebo. In addition, transmission of Ad4-H5-Vtn will be evaluated in all Household Contacts residing with the vaccinated volunteers.
Vaccinees also may participate in a substudy in which they receive a booster vaccination with the licensed Influenza Virus Vaccine, H5N1 (Sanofi Pasteur).
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
03/15/2024
Locations: University of Kentucky, Lexington, Kentucky +3 locations
Conditions: Bird Flu, Influenza
A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines
Completed
The purpose of this study is to evaluate 2 vaccine candidates against anthrax compared to the positive (vaccine) control as studied in normal healthy volunteers.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
03/15/2024
Locations: The Center for Pharmaceutical Research, Kansas City, Kansas +3 locations
Conditions: Anthrax Infection
Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults
Completed
The purpose of this Phase 1 clinical trial is to evaluate the safety, tolerability, and immunogenicity of AV7909 anthrax vaccine in healthy adults. In this study, healthy male and female subjects between 18 and 50 years of age will receive vaccinations via the intramuscular (IM) route at Days 0 and 14. Safety and tolerability will be evaluated via laboratory tests, physical examinations, vital signs, adverse events (AEs), concomitant medications, and local and systemic signs and symptoms of reac... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/14/2024
Locations: Miami Research Associates, Miami, Florida +2 locations
Conditions: Bacillus Anthracis (Anthrax) Infection
A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047
Terminated
PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine \[A549 Cells\], Live, Oral) is an investigational vaccine in development for the indication of active immunization against adenovirus infection. The primary goals of this Phase 1 study are to evaluate safety, pharmacodynamics (viral shedding), and immunogenicity of PXVX0047.
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
03/14/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio +1 locations
Conditions: Adenoviral Infection
Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults
Completed
The objective of this study is to determine the minimum dose of ACAM2000 needed to produce a cutaneous reaction in at least 90% of a population of healthy adults at least 28 years of age and previously vaccinated against smallpox.
Gender:
ALL
Ages:
28 years and above
Trial Updated:
03/14/2024
Locations: PRA International, Lenexa, Kansas +2 locations
Conditions: Smallpox
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
Completed
The purpose of this study is to assess the safety and immunogenicity of an anthrax vaccine. The vaccine schedule and dose will also be assessed.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/14/2024
Locations: Miami Research Associates, Miami, Florida +3 locations
Conditions: Anthrax
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
Completed
The purpose of this Phase 3 clinical trial is to evaluate the immunogenicity and safety of BioThrax anthrax vaccine in healthy adults following 3 doses of BioThrax. Results of this study will be used to support a post-exposure prophylaxis (PEP) indication for BioThrax.
This study will be conducted in the United States (U.S.), in 200 healthy male and female volunteer subjects ages 18 to 65 years.
The duration of study participation for each individual subject will be approximately 128 days (4.2... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/14/2024
Locations: Miami Research Associates, Miami, Florida +3 locations
Conditions: Anthrax
265 - 276 of 948